Cargando…

Improved indocyanine green retention after short-term lenvatinib withdrawal in three patients with hepatocellular carcinoma

Use of lenvatinib, which has a high response rate in advanced hepatocellular carcinoma, sometimes results in tumor shrinkage and resectability of previously unresectable liver cancers. In Asia, including Japan, liver reserve, one of the determinants of resectability, is mainly determined by the indo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sugimoto, Rie, Inada, Hiroki, Tanaka, Yuki, Senju, Takeshi, Aratake, Yoshifusa, Nakanishi, Akira, Miki, Masami, Lee, Lingaku, Hisano, Terumasa, Matsumoto, Yoshihiro, Mano, Yohei, Iguchi, Tomohiro, Sugimachi, Keishi, Okumura, Yukihiko, Taguchi, Kenichi, Furukawa, Masayuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437917/ https://www.ncbi.nlm.nih.gov/pubmed/34176067 http://dx.doi.org/10.1007/s12328-021-01470-y

Ejemplares similares

Risk factors for de novo hepatitis B during solid cancer treatment
por: Sugimoto, Rie, et al.
Publicado: (2020)

Loss of adipose tissue or skeletal muscle during first‐line gemcitabine/nab‐paclitaxel therapy is associated with worse survival after second‐line therapy of advanced pancreatic cancer
por: Miki, Masami, et al.
Publicado: (2021)

Serum zinc levels in cancer patients are low and difficult to elevate when complicated by liver cirrhosis: A retrospective study
por: Sugimoto, Rie, et al.
Publicado: (2023)

Liver metastasis composed of pure squamous cell carcinoma component from pancreatic pure ductal adenocarcinoma: a case report
por: Mano, Yohei, et al.
Publicado: (2023)

Laparoscopic spleen-preserving distal pancreatectomy for a solid-cystic intraabdominal desmoid tumor at a gastro-pancreatic lesion: a case report
por: Sugimachi, Keishi, et al.
Publicado: (2020)

Undifferentiated embryonal sarcoma of the liver occurring in an adolescent: a case report with genomic analysis
por: Shimagaki, Tomonari, et al.
Publicado: (2022)

Treatment Effect and Safety of Nanoliposomal Irinotecan with Fluorouracil and Folinic Acid after Gemcitabine-Based Therapy in Patients with Advanced Pancreatic Cancer: A Multicenter, Prospective Observational Study
por: Miki, Masami, et al.
Publicado: (2022)

Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Niizeki, Takashi, et al.
Publicado: (2022)

Significance of bile culture surveillance for postoperative management of pancreatoduodenectomy
por: Sugimachi, Keishi, et al.
Publicado: (2019)

Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer
por: Lam, Clarissa, et al.
Publicado: (2023)

Simple systemic index associated with oxaliplatin‐induced liver damage can be a novel biomarker to predict prognosis after resection of colorectal liver metastasis
por: Shimagaki, Tomonari, et al.
Publicado: (2022)

Cachexia index as a prognostic predictor after resection of pancreatic ductal adenocarcinoma
por: Shimagaki, Tomonari, et al.
Publicado: (2023)

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study
por: Sugimoto, Rie, et al.
Publicado: (2022)

Cross-species comparison in nonclinical pharmacokinetics of lenvatinib by a simple HPLC with ultraviolet detection
por: Mizuo, Hitoshi, et al.
Publicado: (2023)

Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma
por: Sugimoto, Rie, et al.
Publicado: (2022)

Method validation studies and an inter-laboratory cross validation study of lenvatinib assay in human plasma using LC-MS/MS
por: Mano, Yuji
Publicado: (2018)

Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib
por: Honda, Shuya, et al.
Publicado: (2019)

Persistent epigenetic alterations in transcription factors after a sustained virological response in hepatocellular carcinoma
por: Sugimachi, Keishi, et al.
Publicado: (2022)

Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy
por: Sekiguchi, Shuhei, et al.
Publicado: (2022)

Successful hybrid surgery for ileal conduit stomal varices following oxaliplatin-based chemotherapy in a patient with advanced colorectal cancer
por: Uehara, Hideo, et al.
Publicado: (2020)

Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017)

A Real-Time Near-Infrared Fluorescence Imaging Method for the Detection of Oral Cancers in Mice Using an Indocyanine Green–Labeled Podoplanin Antibody
por: Ito, Akihiro, et al.
Publicado: (2018)

Fluorescence-Guided Surgery for Hepatoblastoma with Indocyanine Green
por: Yamada, Yohei, et al.
Publicado: (2019)

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
por: He, Min-Ke, et al.
Publicado: (2021)

Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report
por: Yokoo, Hideki, et al.
Publicado: (2020)

Lenvatinib: T3 thyrotoxicosis: case report
Publicado: (2021)

Thrombotic microangiopathy associated with lenvatinib therapy
por: Contreras Angulo, Macarena, et al.
Publicado: (2023)

Complete visualization using indocyanine green in thoracic surgery for pulmonary sequestration
por: Nakanishi, Keita, et al.
Publicado: (2023)

Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program
por: Balmelli, Catharina, et al.
Publicado: (2018)

Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma
por: Takinami, Masaki, et al.
Publicado: (2020)

Evaluation of fluorescence imaging with indocyanine green in hepatocellular carcinoma
por: Kaibori, Masaki, et al.
Publicado: (2016)

Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
por: Yano, Shigeki, et al.
Publicado: (2021)

Early radiological response evaluation with response evaluation criteria in solid tumors 1.1 stratifies survival in hepatocellular carcinoma patients treated with lenvatinib
por: Kaneko, Shun, et al.
Publicado: (2020)

Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
por: Zhao, Shu, et al.
Publicado: (2022)

Analysis of Lenvatinib’s Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma
por: Kirino, Sakura, et al.
Publicado: (2020)

Effect of Rifampicin on the Pharmacokinetics of Lenvatinib in Healthy Adults
por: Shumaker, Robert C., et al.
Publicado: (2014)

Lenvatinib for Hepatocellular Carcinoma: A Literature Review
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

Lenvatinib for poorly differentiated carcinoma of the anterior mediastinum
por: Yanagihara, Toyoshi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cdeoq0cc4pigf3fgnrma6ep6hv